Review proposes adaptive maintenance framework for weight loss care after GLP-1 drugs
A new review argues that care after GLP-1 weight loss should move past continue-or-stop and outlines strategies for study, none of them yet validated.
A review published in the journal Obesity Pillars argues that care after weight loss on GLP-1 and dual GLP-1/GIP medications should move beyond a binary choice between indefinite maximum-dose treatment and discontinuation [1][2]. The authors propose a framework they call "adaptive maintenance," aimed at identifying the minimum treatment intensity that preserves meaningful health benefit for each patient [1][2].
The paper is a narrative perspective rather than a new clinical trial. It appears in Volume 20 of Obesity Pillars as article 100327, dated December 2026, published by Elsevier on behalf of the Obesity Medicine Association [2]. The authors are F.H. van Bruggen, M.A. Damhof and E.N. van Roon; all three report no conflicts of interest [1][2]. They examined randomized withdrawal and maintenance trials of incretin-based obesity medications, identified through targeted PubMed searches and screening of reference lists [1][2].
On the evidence, the authors state that continued obesity medication "currently has the strongest direct evidence for limiting weight regain" [1][2]. They add that maintenance requirements vary substantially between individuals, and that some patients may maintain clinically meaningful weight reduction without continued medication [1][2]. The review also reframes regain: weight returning after a dose reduction or after stopping may reflect "the re-emergence of biological pressures favouring weight restoration rather than treatment failure" [1][2].
Strategies the paper lists for formal study include continued obesity medication, monitored dose reduction with predefined re-escalation criteria, switching to an oral agent, reduced-frequency dosing, intermittent rescue therapy and structured lifestyle support [1][2]. An accompanying figure describes an active maintenance phase with structured monitoring of weight trajectory, waist circumference, appetite and satiety, food preoccupation, cardiometabolic markers, functional status, quality of life and patient goals [1].
The authors suggest that early changes in appetite, satiety, food preoccupation, weight trajectory, waist circumference and cardiometabolic markers might flag an emerging relapse before substantial weight regain appears on the scale [1][2]. Those approaches "require prospective validation," the paper says, and the figure notes that the proposed monitoring thresholds and treatment pathways are conceptual [1][2].
Several details are not established. No specific dose levels, monitoring intervals or numeric re-escalation thresholds have been reported, and the review presents no new patient data [1][2]. Among the trials it cites are the STEP 1 extension, which examined weight regain and cardiometabolic effects after semaglutide withdrawal, and a JAMA study comparing continued weekly subcutaneous semaglutide with placebo for weight-loss maintenance [1].
Why it matters for patients
The review does not change what is proven. Continued medication remains the strategy with the strongest direct evidence for limiting regain, and the alternatives it lists — dose reduction, oral switching, less frequent dosing, intermittent rescue therapy — are proposals for study, not validated options [1][2]. The framework does not say who might safely reduce or stop treatment, or how much weight might return under any of the proposed approaches; those questions have not been answered by prospective trials [1][2].
What the paper does suggest is that the conversation after weight loss may shift toward monitoring more than a scale number, including appetite and satiety changes, waist circumference and cardiometabolic markers [1][2]. Whether tracking those signals actually prevents regain is unknown, and the authors call for prospective validation of the idea [1][2]. The review covers GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists as classes; individual maintenance plans, costs and insurance coverage are not addressed in what has been published [1][2].
What happens next
The paper is a call for research, not a trial announcement. It states that the proposed monitoring thresholds and treatment pathways require prospective validation [1][2]. No studies testing the strategies it lists have been announced, and no timeline or funding for such research has been reported [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.